Phase 3 results posted, week of October 26, 2026: 6 industry trials
Industry sponsors posted results for 6 Phase 3 trials on ClinicalTrials.gov so far in the week of October 26 to November 1, 2026. Together the trials enrolled 3,519 participants; the largest, Hoffmann-La Roche's ARNASA trial, enrolled 1,380.
Compiled by code from the stream briefs and public records linked below; no model wrote this page. How we use automation
Each line below links the stream brief and the trial's ClinicalTrials.gov record, largest trial first.
This page updates as the week's records arrive. The week ends on Sunday, November 1, 2026.
The trials
- Hoffmann-La Roche posts results of Phase III astegolimab trial in COPD. Sponsor: Hoffmann-La Roche. Condition: Chronic Obstructive Pulmonary Disease (COPD). Intervention: Astegolimab. Phase: Phase 3. Enrollment: 1,380 (actual). Results first posted October 28, 2026. Record: NCT05595642 (ARNASA).
- Apellis posts results of Phase 3 extension study of pegcetacoplan in geographic atrophy. Sponsor: Apellis Pharmaceuticals, Inc. Condition: Geographic Atrophy Secondary to Age-related Macular Degeneration. Intervention: PEGCETACOPLAN (APL-2). Phase: Phase 3. Enrollment: 792 (actual). Results first posted October 28, 2026. Record: NCT04770545 (GALE).
- Bausch Health posts results of Phase 3 rifaximin SSD study in cirrhosis. Sponsor: Bausch Health Americas, Inc. Condition: Hepatic Encephalopathy. Intervention: Rifaximin SSD. Phase: Phase 3. Enrollment: 517 (actual). Results first posted October 28, 2026. Record: NCT05297448 (RED-C-3132).
- DBV Technologies posts results of Phase 3 DBV712 study in peanut-allergic children. Sponsor: DBV Technologies. Condition: Peanut Allergy. Intervention: DBV712 250 mcg. Phase: Phase 3. Enrollment: 304 (actual). Results first posted October 28, 2026. Record: NCT03859700 (EPOPEX).
- Amgen posts results of Phase 3 erenumab trial in pediatric chronic migraine. Sponsor: Amgen. Condition: Migraine. Interventions: Erenumab Dose 1, Erenumab Dose 2, Erenumab Dose 3. Phase: Phase 3. Enrollment: 284 (actual). Results first posted October 28, 2026. Record: NCT03832998 (OASIS(CM)).
- Bayer posts results of Phase 3 finerenone trial in CKD with type 1 diabetes. Sponsor: Bayer. Conditions: Chronic Kidney Disease, Type 1 Diabetes Mellitus. Intervention: Finerenone. Phase: Phase 3. Enrollment: 242 (actual). Results first posted October 27, 2026. Record: NCT05901831 (FINE-ONE).
By the numbers
- Trials: 6, from 6 lead sponsors.
- Participants: 3,519 in all across 6 trials; median 411 per trial.
- Largest: Hoffmann-La Roche's ARNASA trial, 1,380. Smallest: Bayer's FINE-ONE trial, 242.
- Phases as registered: 6 Phase 3.
How this page is made
Code builds this page from the stream briefs linked above and from each trial's ClinicalTrials.gov record, read when the page was last built: sponsor, condition, intervention, phase and enrollment come from the record. No model writes this page. Registry results are summary data the sponsor posted; the record link opens them in full.